Navigation Links
BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis

PRINCETON, N.J., April 8 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into a license agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY), providing the global healthcare company with access to BioWa's POTELLIGENT(R) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

"We are extremely pleased about our partnership with sanofi-aventis, a global healthcare company with a strong worldwide presence," commented Dr. Masamichi Koike, BioWa's President and CEO. "Sanofi-aventis' world-class R&D organization and global market presence will enable us to promote and extend the benefit of the technology to patients all over the world more efficiently."

"By working with BioWa's POTELLIGENT(R) Technology, we will further improve the mechanism of action of our therapeutic antibodies and make them more potent and more effective against targeted diseases," added Jean-Marc Herbert, Senior Vice President Discovery Research, sanofi-aventis.

Under the terms of the license agreement, BioWa grants sanofi-aventis non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
2. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
3. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
4. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
5. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. EnWave Announces Collaboration and Initial Testing Results with Danisco AS
8. Microbix Announces A New Technology Platform For The SST Project
9. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
10. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
11. Immunotech Laboratories Announces South American Strategy
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
(Date:11/30/2015)... -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, ... Inc., a leading genome informatics company offering highly accurate, ... San Diego -based company has 14 ... Ashley Van Zeeland , Ph.D., who is now ... the deal were not disclosed. Van ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
Breaking Biology Technology:
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
Breaking Biology News(10 mins):